A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer (NCT07333573) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
China42 participantsStarted 2026-01-01
Plain-language summary
This is a single-arm, open-label clinical study evaluating the safety and preliminary efficacy of a novel hypoxia-inducible, bispecific CD73/AXL-targeting CAR-T cell product, XW-LTH-03, in patients with stage IV gastric cancer (GC). The primary objective is to assess the safety and tolerability of XW-LTH-03 infusions. Secondary objectives include the evaluation of its antitumor efficacy and the characterization of its pharmacokinetic profile by measuring the in vivo expansion and persistence of the CAR-T cells. Exploratory analyses aim to identify potential biomarkers associated with clinical response and toxicity, as well as to investigate the cellular and molecular mechanisms underlying potential treatment resistance.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged 18 to 75 years, male or female.
✓. Clinically judged as unresectable Stage IV gastric cancer that has progressed on or is intolerant to standard therapy, or patients who voluntarily forego standard therapy.
✓. Patients must provide tumor tissue samples, with positive AXL and CD73 confirmed by immunohistochemical (IHC) staining at a central laboratory: AXL positivity rate ≥50% with staining intensity ≥++, and CD73 positivity rate ≥30% with staining intensity ≥+.
✓. ECOG Performance Status score of ≤ 1.
✓. Life expectancy of ≥ 3 months.
✓. At least one measurable lesion (≥ 1 cm).
✓. More than 4 weeks since the last failed treatment, and any toxicities from previous treatments must have recovered to Grade ≤ 1.
✓. Adequate organ function and bone marrow reserve, as defined by the following laboratory values within a specified period before enrollment:
Exclusion criteria
What they're measuring
1
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: 3 months
2
Incidence of Dose-Limiting Toxicities (DLTs)
Timeframe: 3 months
3
Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
. Active, known, or highly suspected autoimmune disease.
✕. Patients with brain metastases who have active central nervous system symptoms. (Note: Patients with brain metastases who completed radiotherapy at least 3 months prior to enrollment and remain asymptomatic from CNS disease may be eligible).
✕. Active, uncontrolled systemic infection.
✕. Receiving high-dose corticosteroids (\>10 mg/day of methylprednisolone or equivalent doses of other corticosteroids) or other immunosuppressive therapy within 14 days prior to enrollment.
✕. History of severe allergy to other monoclonal antibodies.
✕. Intolerance or allergy to the investigational drug.